Erosion risks

• Physician engagement can plateau once U.S. physician penetration is already high.
• Competing professional networks, medical publishers, EHRs and AI assistants can draw clinician attention away from Doximity.
• Privacy, security or content-trust failures could reduce clinician willingness to participate.

Leading indicators

• U.S. physician penetration
• Quarterly active prescribers across newsfeed, workflow and AI
• Member retention and profile freshness

Counterarguments

• High clinician membership does not automatically translate into proportional customer budget share.
• Physicians can multi-home across LinkedIn, Medscape, Sermo, EHR portals, journals and hospital tools.

Erosion risks

• Epic, Oracle Health, Microsoft Teams, Zoom and hospital-native communication tools can absorb workflow use cases.
• AI assistants can become commoditized if clinical references, scribing and summarization are widely available.
• Workflow tools are often free to clinicians, limiting direct monetization and increasing dependence on customer budgets.

Leading indicators

• Workflow quarterly active prescribers
• AI quarterly active prescribers
• Dialer call and text volumes

Counterarguments

• Workflow engagement is valuable, but the system of record remains the EHR for many clinical tasks.
• Free clinician tools may not create hard contractual lock-in if alternative tools become equally convenient.

Erosion risks

• Privacy rules, HIPAA-sensitive workflows and state data laws can restrict data use.
• Hospitals, EHR vendors, claims-data providers and pharma agencies can use their own datasets for targeting.
• AI model improvements may reduce the value of proprietary workflow-specific data if competitors access comparable clinical sources.

Leading indicators

• Profile completion and update rates
• Newsfeed personalization engagement
• Campaign ROI and customer expansion

Counterarguments

• Doximity's data advantage is mainly U.S. clinician-specific, not a broad healthcare claims or EHR dataset.
• Some targeting value depends on third-party and public data that competitors may also access.

Erosion risks

• Pharmaceutical policy uncertainty, tariffs or drug-pricing pressure can reduce HCP marketing budgets.
• Large customers and agencies can renegotiate contracts or shift dollars to alternative channels.
• Revenue concentration among large customers can make churn or budget cuts material.

Leading indicators

• Net revenue retention
• Customers with TTM subscription revenue greater than $500,000
• Subscription revenue percentage

Counterarguments

• Subscriptions are not as sticky as mission-critical software of record.
• Pharma and health-system marketing buyers can run parallel campaigns across multiple vendors.

Erosion risks

• Sponsored content, pharma marketing or AI mistakes could undermine physician trust.
• A data breach or misuse of clinician or patient-related information would damage the brand.
• Competitors with strong medical content brands can challenge clinician attention and trust.

Leading indicators

• Best in KLAS rankings
• App ratings and reviews
• Newsfeed quarterly active prescribers

Counterarguments

• Brand trust is strong with physicians, but customers buy measurable ROI and can compare vendors.
• Medscape, medical journals, EHR vendors and hospital systems also have trusted clinical relationships.